🎉 We are excited to announce the launch of Resound Research for Reproductive Health, a new collaborative fiscally sponsored by @TidesCommunity! Although we will no longer be known as TxPEP, we will continue to conduct the rigorous #repro research in #TX and beyond. 🎉
Resound Research for Reproductive Health's research affiliate Dr. Tony Ogburn is featured in this investigation of doctors leaving Texas due to increasingly stringent abortion laws. https://t.co/jYE5LDooFN
“If I’m confused, I can only imagine that other doctors are confused. Patients don’t want a confused doctor.” Dr. Anitra Beasley https://t.co/H5U7txXL3o
#abortion#texas#pregnancy
A new report shows how health care providers are still unable to provide standard medical care in states with abortion bans. @ANSIRH https://t.co/0QzsVXSxau
Texas Attorney General Ken Paxton is suing the Biden administration to block a federal HIPAA rule that protects medical records from being accessed in criminal investigations if a patient seeks abortion care out of state:
https://t.co/01yCQhq9h0
A new Perspectives piece in @NEJM by Elizabeth Tobin‑Tyler and Resound Research's affiliated researcher Samuel L. Dickman emphasizes the weaknesses of policy solutions for survivors of intimate partner violence, especially in the context of #abortion bans. https://t.co/r5GCJCDX3x
This month, we’re celebrating a historic milestone in #repro health access: the 1-year anniversary of FDA approval of the first over-the-counter birth control pill in the US! 🥳💊
Here's what #FreeThePill coalition members told FDA advisors about why OTC access is essential 🧵
Today we announced a new funding opportunity: Health and economic outcomes, post-Dobbs. The deadline for proposals is September 12.
https://t.co/ipizKXEVzf
Please consider submitting a proposal or sharing this request for proposals with a colleague or collaborator.
Now hiring--research assistant! This position is responsible for a range of supportive functions for the study teams, including participant management – outreach, scheduling, and remuneration. https://t.co/AqzYvkGrBu
‼ While this might seem like a "win" to some, it’s important to note that this threat is far from over.
At least 3 states have opposed the FDA’s expanded access to medication abortion, meaning this fight will likely continue.